Generic Mavyret (Glecaprevir/Pibrentasvir)
Same active ingredient — glecaprevir/pibrentasvir — as Mavyret®, at a substantially lower price. Produced by licensed pharmaceutical manufacturers.
The same active ingredient, without the originator price
Generic glecaprevir/pibrentasvir is the equivalent of branded Mavyret® — not a different medicine, and not a “knockoff.”
Any switch between brand and generic should be discussed with your prescribing doctor. Reference prices are indicative public list prices and vary by market.
Available generic glecaprevir/pibrentasvir options
Every option contains glecaprevir/pibrentasvir and requires a valid prescription. Grouped by strength.
Availability varies by destination. All options are dispatched after pharmacist review of your prescription.
What Mavyret® typically costs — and the generic alternative
Typical branded reference prices by market, next to our generic glecaprevir/pibrentasvir price.
| Market | Branded Mavyret® — reference price | Generic glecaprevir/pibrentasvir — OnlineMeds |
|---|---|---|
| United States | ~$26,000 per 8-week course (brand list price) branded list price |
from
$2,225.00 / tablet
tracked worldwide shipping · Rx required
|
| United Kingdom | NHS price confidentially negotiated, not published branded list price |
from
$2,225.00 / tablet
tracked worldwide shipping · Rx required
|
| Australia | PBS price confidentially negotiated, not published branded list price |
from
$2,225.00 / tablet
tracked worldwide shipping · Rx required
|
Reference prices are indicative public list prices for the originator brand. Prices vary by destination & quantity — not a promised discount.
Glecaprevir/Pibrentasvir, explained simply
Written and reviewed by our pharmacist team. Informational only — your doctor directs your treatment.
Glecaprevir/pibrentasvir is a pan-genotypic direct-acting antiviral combination used in the treatment of chronic hepatitis C. It is sold by its originator as Mavyret in the United States and as Maviret in the United Kingdom, Europe and Australia. Generic versions containing the same two active ingredients at the same strengths are produced by licensed pharmaceutical manufacturers and are prescription-only, as the brand is.
Each tablet contains glecaprevir 100 mg and pibrentasvir 40 mg. The two act at different points in the hepatitis C virus lifecycle: glecaprevir inhibits the NS3/4A protease the virus needs to process its own proteins, and pibrentasvir inhibits NS5A, a protein involved in viral replication and assembly. Combining the two is what makes the regimen pan-genotypic — it is used across hepatitis C genotypes 1 to 6 rather than being matched to a single genotype.Never change your dose on your own.
Report new or worsening symptoms to your doctor promptly. This is not a complete list — see the patient information leaflet.
Store as directed on the patient information leaflet, usually at room temperature away from moisture and out of reach of children. Always follow the storage guidance supplied with your medicine.
Hepatitis C treatment is priced by the course, not by the month, so the number of weeks moves the total more than the price of any single pack does. An eight-week course is materially less medicine than a twelve-week one, which is part of why glecaprevir/pibrentasvir was priced differently from the sofosbuvir-based regimens that came before it. When you compare quotes, compare complete courses — a lower per-pack price spread over a longer course is not necessarily the lower total.
Most of our hepatitis C range is built around sofosbuvir — see generic Epclusa (sofosbuvir/velpatasvir) and generic Harvoni (sofosbuvir/ledipasvir). Glecaprevir/pibrentasvir contains no sofosbuvir at all, which is why it appears in different clinical situations rather than as a straight substitute for them. Which regimen applies to you depends on genotype, whether you have been treated before, liver and kidney assessment, and the other medicines you take. For background on testing and treatment, see our hepatitis information hub.
Mavyret® vs generic glecaprevir/pibrentasvir
| Attribute | Mavyret® (brand) | Generic glecaprevir/pibrentasvir |
|---|---|---|
| Active ingredient | Glecaprevir + pibrentasvir | Glecaprevir + pibrentasvir Same |
| Strengths | 100 mg / 40 mg per tablet | 100 mg / 40 mg per tablet Same |
| Dosage form | Oral tablet | Oral tablet Same |
| Originator | AbbVie | licensed pharmaceutical manufacturer |
| Typical dosing | Three tablets once daily with food | Three tablets once daily with food Same |
| Prescription required | Yes | Yes Same |
| Typical cash price | ~$26,000 per 8-week course (brand list price) (United States reference) | from $2,225.00 / tablet |
| Availability | National pharmacies & insurance coverage | Ships worldwide from OnlineMeds — Rx required |
Equivalence refers to the active ingredient, strength, and form. Discuss any switch with your prescribing doctor.
A pharmacy, not a marketplace
Every order is sourced, checked, and dispatched by our own licensed pharmacy team.
Frequently asked questions
Quick answers about equivalence, prescriptions, legality, and delivery. Tap a question to expand.
What is the brand name for glecaprevir/pibrentasvir?
How many tablets a day is it?
Is generic glecaprevir/pibrentasvir the same as Mavyret?
Why is it an eight-week course when other treatments are twelve?
Do I need a prescription?
Simran Jha is a licensed clinical pharmacist with 17 years of experience. She holds a B.Pharm and M.Pharm from Dr. YSR University of Health Sciences. At OnlineMeds, she reviews medicine and health content to help ensure it is accurate, evidence-based, and easy to understand.
Informational only. Used as prescribed by a licensed medical professional. This content is for informational purposes only and does not replace advice from your doctor or pharmacist. Consult a healthcare professional before use.
This page draws on public information from recognised health authorities and cancer organisations. Always follow the guidance of your own doctor.